KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Adaptive Biotechnologies (ADPT) Common Equity: 2018-2024

Historic Common Equity for Adaptive Biotechnologies (ADPT) over the last 7 years, with Dec 2024 value amounting to $202.7 million.

  • Adaptive Biotechnologies' Common Equity fell 8.64% to $204.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $204.4 million, marking a year-over-year decrease of 8.64%. This contributed to the annual value of $202.7 million for FY2024, which is 34.27% down from last year.
  • Per Adaptive Biotechnologies' latest filing, its Common Equity stood at $202.7 million for FY2024, which was down 34.27% from $308.4 million recorded in FY2023.
  • In the past 5 years, Adaptive Biotechnologies' Common Equity ranged from a high of $743.3 million in FY2020 and a low of $202.7 million during FY2024.
  • Over the past 3 years, Adaptive Biotechnologies' median Common Equity value was $308.4 million (recorded in 2023), while the average stood at $325.1 million.
  • As far as peak fluctuations go, Adaptive Biotechnologies' Common Equity skyrocketed by 30.16% in 2020, and later slumped by 34.27% in 2024.
  • Yearly analysis of 5 years shows Adaptive Biotechnologies' Common Equity stood at $743.3 million in 2020, then declined by 18.72% to $604.1 million in 2021, then declined by 23.16% to $464.2 million in 2022, then tumbled by 33.56% to $308.4 million in 2023, then plummeted by 34.27% to $202.7 million in 2024.